[Latest] Global Serological Testing Market Size/Share Worth USD 8,100 Million by 2033 at a 6.70% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 19, 2024 01:30 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Serological Testing Market Size, Trends and Insights By Technology (ELISA, NAT,...
Theratechnologies dévoile le plan et les caractéristiques initiales de l'essai PROMISE-US sur l'ibalizumab chez les personnes vivant avec le VIH ayant reçu de nombreux traitements et présentant une multirésistance aux médicaments
October 17, 2024 07:30 ET
|
Theratechnologies
MONTRÉAL, 17 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
October 17, 2024 07:30 ET
|
Theratechnologies
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Theratechnologies présentera des données à l’IDWeek 2024 soulignant les progrès réalisés dans le traitement et la prise en charge des complications chez les personnes vivant avec le VIH
October 09, 2024 07:30 ET
|
Theratechnologies
MONTRÉAL, 09 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
October 09, 2024 07:30 ET
|
Theratechnologies
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
The Wistar Institute and University of Pennsylvania Scientists Identify Potential Target Gene within Certain HIV Reservoir Cells
October 03, 2024 15:08 ET
|
The Wistar Institute
Philadelphia, PA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- New findings could lead to different research tactics for scientists investigating a cure for HIV. Results from The Wistar Institute’s Lieberman...
Rita & Alex Hillman Foundation Awards $250,000 in Funding to Advance Early-Stage, Equity-Focused Health Innovations
September 24, 2024 11:00 ET
|
Rita & Alex Hillman Foundation
RITA & ALEX HILLMAN FOUNDATION AWARDS $250,000 IN FUNDING FOR EARLY-STAGE, EQUITY-FOCUSED INNOVATIONS FOR VIOLENCE PREVENTION, BIRTH JUSTICE, HIV TESTING
Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria
July 18, 2024 11:35 ET
|
Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) signed a distribution agreement for the Republic of Nigeria that can generate the company €7.9 billion revenue.
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
July 01, 2024 16:31 ET
|
HOOKIPA Pharma Inc.
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency...
bioLytical Donates 1200 HIV Testing Kits Across the United States to Support National HIV Testing Day
June 27, 2024 09:00 ET
|
bioLytical Laboratories Inc.
bioLytical helps boost testing with free HIV rapid test donations to KFF and the Greater Than HIV campaign to support national testing efforts